Rook random Flashcards

(208 cards)

1
Q

What are the subtypes of seb K?

A

acanthotic
hyperkeratotic
melanoacanthoma
adenoid
clonal
irritated

The following are considered to be clinical variants of SK:
* Stucco keratosis.
* Inverted follicular keratosis
* Dermatosis papulosa nigra

Acanthotic SK have a markedly thickened
epidermis and horny invaginations which appear as pseudo-horn
cysts. Adenoid SK have numerous thin tracts of epidermal cells
extending from the epidermis and branching and weaving through
the dermis, often containing only a double row of basaloid cells.

Clonal SK are a rare variant with well-demarcated interepithelial nests of pale or basaloid cells occurring within the epidermis. This intraepidermal proliferation is
described as the Borst–Jadassohn phenomenon, which is also seen
in hidroacanthoma simplex and Bowen disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is a melanoacanthoma?

A

Melanoacanthoma is often described as a rare variant, but it has been found to comprise 8–9% of SK in some pathology series.
Melanoacanthomas have hyperpigmentation throughout all layers of the thickened epidermis and melanocytes with pronounced dendrites throughout the epidermis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

can seb K’s appear on mucosal surfaces?

A

SK can appear at any site other than mucosal surfaces, most commonly on the temples, chest, back, neck, scalp, dorsal hands and
forearms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what size of seb K. is too big for cryo?

A

Lesions over 15 mm in size are harder to treat evenly with
cryotherapy and surgical treatment is often preferable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

For patients with multiple SK, topical treatment by lesional
application of trichloracetic acid solution (50–75%) is effective

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

stucco keratosis have been found to harbour PIK3CA mutations

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q
A

Warty dyskeratoma usually presents in older adults on sun-exposed skin of the
scalp, face or neck.

WDs have been observed during vemurafenib treatment
Smoking is thought to be the main cause of oral lesions

Other symptoms may include recurrent foul-smelling cheese-like discharge or bleeding with trauma.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Re: clear cell acanthoma
The cytoplasm of the clear cells contains
glycogen, which stains with periodic acid–Schiff with diastase sensitivity. Phosphorylase enzyme necessary for the degradation of
glycogen has been found to be absent in CCA keratinocytes. Electron microscopy reveals the displacement of tonofibrils with glycogen

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q
A

Clear cell acanthoma

CCA usually presents as a red or red-brown asymptomatic dome-shaped papule or nodule with a ‘stuck-on’ appearance.
The surface may look moist or crusted, and bleeding can occur with
trauma.
A collarette of fine peripheral scale is occasionally present

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q
A

Dermoscopy shows an abundance of striking glomerular blood vessels with pin-point capillary loops in a streaky, curvilinear, reticu-
lated pattern. This vascular pattern of dotted and coiled vessels in a serpiginous arrangement gives it a characteristic ‘string of pearls’ appearance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what stains are positive and negative in a desmoplastic melanomma?

A

Staining with SOX10 and/or S100 protein usually marks the
spindle-shaped cells whereas Melan-A and HMB-45 antigen
stainingare always negative

Desmoplastic melanoma. This is a proliferation of spindle-shaped
melanocyteswithnoorlittlepigmentation,withscar-likefibrosis
in the dermis associated with a conspicuous inflammatory infil-
trate. It can display at the same time attributes of
melanocytic, fibroblastic and schwannian differentiation, often
variably intermingled. The differential diagnosis includes
cutaneous sarcomas or spindle-cell squamous cell carcinoma.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How do you distinguish between a spitz naevus and spitz MM?

A

In the context of this Spitz spectrum, the diagnosis between a Spitz naevus and a Spitzoid MM is particularly difficult and
uncertain on morphological grounds. It is often determined on genomics.

The Spitz spectrum is characterised by gene fusion involving ALK, ROS1, MET, RET, NTRK1, NTRK3, MAP3K8 and always lacks mutations in the MAPK pathway, such as canonical BRAF, NRAS, KIT, GNAQ or GNA11 mutations.

Searching for the latter can help classify a lesion as non-Spitz MM, despite its Spitzoid morphology. The prognosis of a lesion within the Spitz spectrum is better assessed using cytogenetics, involving FISH fluorescence in situ hybridisation (FISH) techniques or array
comparativegenomichybridisation (aCGH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

how do you distinguish a blue naevus from a malignant blue naevus?

A

Blue naevus-like MM (malignant blue naevus)
is molecularly related to uveal MM and shares many molecular and cytogenetic similarities. An integrated histomolecular diag-
nosis is based on canonical alteration of GNAQ, GNA11, PLCB4 or CYSLTR2 mutations, with additional alterations on
SF3B1 or BAP1. Redundant cytogenetic alterations with
gains in 6p and/or 8q, monosomy 3 ,and loss in 1p are similar to those detected in uveal MM.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is a melanocytoma?

A

Pigmented epithelioid melanocytoma/pigment synthesising melanoma (animal-type melanoma). These are rare melanocytic tumours (melanocytoma), considered as intermediate in nature, with metastatic potential limited to the regional lymph nodes,
although this is not clear at all. Histologically, they show heavily pigmented spindle-shaped or epithelioid melanocytes which
mimic MM, composed of heavily pigmented epithelioid or dendritic cells. These lesions usually harbour both BRAF V600E
mutations and loss-of-function alterations affecting PRKAR1A or PRKCA gene fusion. Such lesions can occur in a sporadic setting or in patients affected with Carney complex.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what stains can be used to diagnose melanoma?

A

S100 protein is expressed by 99% of all MM
and melanocytic naevi but also by several other tumours that harbour cartilaginous, nervous or myoepithelial differentiation.
A more recent marker is SOX10, which displays the same or a slightly higher sensibility compared with S100, with a different
pattern of specificity, staining the nuclei of neoplastic cells, which can aid in asserting ascents of cells and nuclear pleomorphism.
Mart-1 (Melan-A) and HMB-45 are more specific, but lack some
sensitivity, and in particular do not stain desmoplastic MM.
Many other markers are useful in the diagnosis of MM, including MITF. Next-generation antibodies, directed against canonical
molecularalterations,suchasNTRK,ALK,ROS1,MET,RET,BRAF V600E, NRAS Q61R, HRAS and PRKAR1A, are particularly used
by referral centres as a substitute for genetic testing.

PRAME expression might be useful in distinguishing >90% of benign versus malignant melanocytic neoplasms. PRAME is particularly useful in assessing the margins of lentiginous MM such as LM and ALM. Clonal loss of expression of p16, associated or
not with copy number aberrations of the CDKN2A locus by FISH or aCGH, has been reported as highly specific for borderline and
malignant Spitzoid neoplasms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what is FISH testing for melanoma?

A

Fluorescence in situ hybridisation. Fluorescence in situ hybridisa-
tion (FISH) detects copy number changes as well as chromosomal translocations and allows the direct visualisation of tissue
histology. When performed with a panel of four probes, FISH seems to represent a sensitive and molecular tool for the
diagnosis of non-ambiguous melanocytic lesions, whereas in the context of ambiguous melanocytic tumours, results are still
controversial. FISH is also a useful tool to detect gene fusions for Spitz neoplasms, some of which have an important prognostic
and theragnostic value

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is RNA sequencing in regard to melanoma diagnosis?

A

RNA sequencing. Chromosomal rearrangements leading to the formation of fusion transcripts are a frequent driver in the Spitz group of neoplasms (ALK, BRAF, NTRK1, NTRK3, ROS1, MET, MAP3K and RET) and some PEM (PRKCA).

Transcriptome sequencing (RNA-seq) has emerged as an effective method to detect fusion transcripts and is now considered the most reliable method to detect fusions, while immunohistochemistry and FISH are cost-effective alternatives in some cases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

which organs do melanoma metatsasize to?

A

Lung, brain, liver and bones are the most
common metastasis sites.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

what are the Main prognostic factors for primary
melanoma?

A

(worst prognosis is for head and neck MM
in elderly males

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

how is the breslow thickness calculated?

A

The measurement (in millimetres)
of the distance between the overlying epidermal granular layer
and the deepest level of invasion of the primary lesion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Re: melanoma staging

All patients with nodal metastases including micrometastases detected by
immunohistochemistry (i.e. sentinel node involvement) are clas-
sified as stage III.

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

what is the 5 year survival rate for stage III melanoma?

A

The 5-year survival rates are
93%, 83%, 69% and 32% for patients with stage IIIA, IIIB, IIIC and
IIID MM, respectively

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

what are the follow up guidelines for melanoma patients?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

what are the margins for melanoma excision?

A

Current best available evidence, surgical recommendation:
for melanoma in situ is a 0.5–1cm margin;

for invasive melanoma
<1.0mm thick, 1cm margin;

for melanoma 1.0–2.0 mm thick, 1–2cm
margin;

and for melanoma >2.0mm, 2cm margin

The appropriate depth for any melanoma resection is also debated
but typically recommended to extend to the deep adipose tissue
for melanoma in situ and thin melanoma, and through the subcutaneous fat to the plane of the muscular fascia for deeper melanomas.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
What techniques are there to assist with the subclinical extension of LM or LMM?
Options include standard excision with side-to-side closure versus delayed reconstruction to allow for permanent section margin analysis; Mohs surgery with immunostaining; and permanent sectioning mapped (i.e. ‘slow Mohs’) or staged mapped (i.e. ‘square’) techniques. Consistent with staged permanent section margin methods, studies of Mohs surgery with immunohistochemistry report 0.9–1.5cm surgical margins were histological margin tumour-free in 95–97% of melanoma in situ lesions on the head and neck, with a 0.5cm margin clearing 65% of these lesions
26
The presence of activating mutations in BRAF in about 50% and in NRAS in about 20% of all melanomas offers additional therapeutic opportunities.
T Simultaneous inhibition of BRAF and MEK improves response rates and survival compared with BRAF inhibition alone. The addition of MEK inhibition not only improves survival, it also reduces resistance development and decreases the cutaneous toxicity seen with single-agent BRAF inhibition Available oral combinations include dabrafenib plus trametinib, vemurafenib plus cobimetinib and encorafenib plus binimetinib. Relevant prognostic factors include lactate dehydrogenase, higher performance status and less than three organ sites with metastases. In contrast to immunotherapy, targeted therapy is generally administered indefinitely. Discontinuation of targeted therapy might lead to tumour regrowth. Interestingly, however, data also suggest that resistance to targeted therapy maybe partially reversed by intermittent dosing or by drug holiday
27
A small subset accounting for approximately 10% of acral and mucosal melanomas expresses mutations in KIT and a minor portion of uveal melanomas exhibit mutations in GNA11/GNAQ (guaninenucleotidebindingprotein (Gprotein), qpolypeptide) (approximately1%)
T Only approximately one-third of melanomas with KIT mutations are responsive to targeted therapy.
28
Patients with advanced stage III melanoma with macrometastases are good candidates for neoadjuvant therapy, preferentially in a clinical trial
T
29
First line treatment options for unresectable stage III and IV are anti-PD-1-based therapies (nivolumab, pembrolizumab alone or in combination with ipilimumab)
T For melanoma patients harbouring a BRAF mutation, targeted therapy with BRAF and MEK inhibitors (dabrafenib plus trametinib, vemurafenib plus cobimetinib or encorafenib plus binimetinib) is an additional valu- able treatment option that is recommended as a second line option except in symptomatic patients
30
Pembrolizumab and nivolumab can be administered either as monotherapy (200 mg IV every 3 weeks and 240 mg IV every 2 weeks) or in combination with ipilimumab (1 mg/kg IV every 3 weeks followed by ipilimumab 3 mg/kg for the first four infu- sions; 3 weeks after the last combined treatment session continue with 240 mg IV every 2 weeks). Response rates ranged from 35% to 60% of treated patients.
T
31
Targeted therapy options include oral dabrafenib (150 mg BD) plus trametinib (2 mg QD), oral vemurafenib (960 mg BD) plus cobimetinib (60 mg QD for 21 days in a 28-day cycle) and oral encorafenib (450 mg QD) plus binimetinib (45 mg BD).
32
The most common dermatological side effects of treatment with immune-checkpoint inhibitors include lichenoid dermatitis, pruritus and vitiligo
33
Cutaneous reactions predominantly start to appear during the first weeks of treatment and persist during BRAF inhibition. Vemurafenib causes clinically relevant ultraviolet A (UVA) dependent phototoxicity that requires adequate UV pro- tection, whereas phototoxic reactions have not been described with dabrafenib and encorafenib
34
MEK inhibitors typically cause xerosis cutis and papulopustular rashes in the first 2–6 weeks of treatment. In this situation, local steroids and systemic administration of doxycycline should be evaluated. The topical administration of acne treatment (i.e. benzoyl peroxide) may worsen the clinical picture and should not be prescribed.
35
what is the prognosis of merkel cell carcinoma?
Merkel cell carcinoma (MCC) is a highly aggressive carcinoma of the skin with neuroendocrine differentiation demonstrating high rates of recurrence and metastasis. Indeed, the 5-year rate for MCC-specific survival in the USA is only about 76% for localised, 53% for regional and 19% for distant disease.
36
MCC is a tumour of advanced age with the high-est incidence rate observed in those 85 years or older, with an age-adjusted rate of 14.6 per 100 000 for males and 5.5 for females.
T
37
MCCs are most often found on the sun-exposed skin areas of the white population who are older than 50 years. Indeed, MCC is much more common in white than in black patients, i.e. 0.31 and 0.01 per 100 000 persons, respectively
38
The mean age of patients at the time of initial diagnosis is about 76 years for women and 73 years for men. In fact, 71.6% of patients are older than 70. MCC predominates in men (61.5%).
T The mean age of patients at the time of initial diagnosis is above 70 years. Notably, there is a 5–10-fold increase in incidence after the age of 65.
39
MCC occurs much more frequently in severely immunosup-pressed populations, such as organ transplant patients, patients with haematolymphoid disorders or acquired immune deficiency syndrome
T Indeed, the mean age at diagnosis in organ transplant recipients is almost 20 years lower compared with immunocompetent patients. In organ transplant recipients, MCCs tend to develop 7–8 years post-transplantation and affect the head and neck areas, often in the presence of other UV-induced skin cancers.
40
Indeed, the mean age at diagnosis in organ transplant recipients is almost 20 years lower compared with immunocompetent patients. In organ transplant recipients, MCCs tend to develop 7–8 years post-transplantation and affect the head and neck areas, often in the presence of other UV-induced skin cancers.
T Immune control of MCC is supported by a number of observations. For example, MCC occurs more frequently and at younger ages in severely immunocompromised populations, such as organ transplant patients, patients with haematolymphoid disor-ders or human immunodeficiency virus (HIV) infected individuals. Immunocompromised patients also have a worse prognosis. The observation that the incidence rates for MCCs increase for persons living in areas of lower latitudes, and that MCC is most often found on the sun-exposed skin of white people, suggest UV exposure as one of the major environmental risk factors
41
Merkel cells are located at the epidermal–dermal junction, mostly in associ-ation with appendage structures, and act as light touch receptors
42
The carcinogenesis of MCC is associated either with the clonal inte-gration of Merkel cell polyomavirus (MCPyV) DNA into the host genome or UV-induced DNA mutations, both resulting in similar cellular aberrations
T In addition, detection of high tumour mutation burden, prominent UV signature and frequent association with squamous cell carcinoma and precursors support an epidermal origin for MCPyV-negative MCC
43
MCC almost always infiltrates the dermis and/or subcutaneous tissues without connection with the overlying epidermis, although connec-tions with appendages might be observed
44
Classic MCC tumour cell features include a high nucleocytoplasmic ratio, scant cytoplasm, round nucleus with frequent nuclear moulding and fine, vesicular chromatin (so-called ‘salt and pepper’).
T Histological features of the tumours associated with poor outcome include tumour size (≥5 mm), extension into the subcutaneous tissue, vascular invasion and a blurred boundary.
45
MCC tumours coexpress epithelial markers, notably cytokeratins and epithelial cell adhe-sion molecule (EPCAM), and neuroendocrine markers, including chromogranin A, synaptophysin, CD56 and INSM1. Of note, frequent positivity of MCC tumour cells for markers observed in haematological (PAX5 (a B-cell-specific activating protein) and TdT (terminal desoxynucleotidyl transferase) and soft tissue malignancies (CD99) should not lead to misdiagnoses
T
46
Morphological similarities and shared dual epithelial and neuro-endocrine differentiation make metastasis of an extracutaneous neu-roendocrine carcinoma, mostly from the lung, the most challenging differential diagnosis for MCC. Immunohistochemistry is a crucial tool in resolving these entities. Cytokeratin 20 expression with a paranuclear dot-like pattern as well as neurofilament and SATB2 are hallmarks of MCC, whereas these markers are almost lacking in extracutaneous neuroendocrine tumours
T By contrast, expressions of thyroid transcription factor 1 (TTF-1) and cytokeratin 7 are frequently observed in extracutaneous cases, and are restricted to only a small subset of MCC (<10%)
47
The detection of MCPyV either by immunohistochemistry or polymerase chain reaction (PCR) is an additional performant tool to confirm the primary skin origin of MCC
48
MCC is a fast-growing, asymptomatic solitary, firm, non-sensitive, flesh to red to violaceous nodule with a smooth, shiny surface . MCC usually develops and grows rapidly over weeks to months on chronically sun-damaged skin.
Thus, the predominant sites are the head and neck (more than half of cases) and extremities (one-third of cases), whereas the trunk as well as the oral and genital mucosa are involved in less than 10% of cases.
49
Depending on MCC aetiology, several phenotypic variations can be detected. Features mostly observed in MCPyV-negative tumours are irregular/spindle nuclei, abundant clear cytoplasm, the pres-ence of ulceration, intraepidermal involvement and asso-ciation with epidermal tumours or the presence of a divergent dif-ferentiation. Although the ability of cytological analysis to predict virus status remains to be tested, association of MCC with in situ or invasive squamous cell carcinoma is highly suggestive of a MCPyV-negative tumour. In addition, an ‘aberrant’ immunopheno-type, with frequent negativity for cytokeratin 20 (9%) and/or neuro-filament (25%) and weak positivity for cytokeratin 7 (8%) and TTF-1 (11%), are more frequently observed in MCPyV-negativeMCC cases than in others
50
The clinical appearance of MCC results from the fact that the tumour usually grows hemispherically in depth, so that the intact epidermis is stretched.
51
Ulceration of primary MCC tumours is rarely observed and mostly occurs in advanced disease.
In contrast, satellite metastases are frequently observed
52
They often exhibit overlying telangiectasia, making MCC lesions easily confused with basal cell carcinoma
53
To aid the clinical diagnosis, the acronym AEIOU has been pro-posed to describe the most common clinical characteristics of MCC: asymptomatic, expanding rapidly, immune suppression, older than 50 years, ultraviolet-exposed site on fair skin. Almost 90% of MCCs exhibit at least three of these five features
54
what are the prognostic factors of MCC?
In addition to the prognostic histopathological markers discussed earlier, several favourable prognostic factors have been identified, including primary tumour size ≤2 cm, local disease, female gender and primary tumour localised on the upper limb. In addition, several studies confirmed the prognostic significance of unim-paired immune function. However, lymph node status is the most important independent predictor including occult microscopic nodal involvement, which is present in one-third of patients The T category is classified by measuring the maximum dimen-sion of the primary tumour: 2 cm or less (T1), more than 2 but less than 5 cm (T2) and more than 5 cm (T3); extracutaneous invasion into bone, muscle, fascia or cartilage is classified as T4. Increasing tumour size is associated with a modestly poorer prognosis The N category is related to the nodal tumour burden. Due to the high propensity for clinically inapparent lymph node metas-tases, true lymph node negativity by pathological evaluation (pN0) alludes to a better prognosis compared with patients whose lymph nodes are only evaluated by clinical or ultrasound examination (cN0). N1a represents microscopic and N1b macroscopic (i.e. clini-cally apparent) lymph node metastases. N2 refers to the presence of in-transit metastases. The M category for distant metastatic disease comprises three (b) groups: M1a includes distant skin, subcutaneous tissues or lymph nodes; M1b is lung; and M1c all other visceral organ sites or brain metastases.
55
what investigations are recommended for MCC?
After a confirmed diagnosis of a primary MCC, clinically indicated imaging may be useful in identifying distant metastases considering the metastatic potential of this tumour. In general, it is currently rec-ommended to perform at least an ultrasound of the draining lymph nodes and the abdomen as well as a chest X-ray. It should be noted, however, that the main value of chest X-ray at the time of diagnosis is to provide a basis of comparison for future diagnostics. Positron emission tomography/computed tomography (PET/CT) scanning is gaining importance in diagnostic imaging of MCC and may be preferred even at initial diagnosis. Due to the high frequency of lymphatic metastases, sentinel lymph node biopsy (SLNB) is generally advised to allow pathological evaluation of the sentinel lymph nodes, especially since micrometastases seem to denote poorer prognosis. When distant metastases are suspected, the appropriate organ imaging should be performed. The most frequently involved organ systems are the skin, lymphatics and liver; however, all organ systems may be potentially affected including the central nervous system. Somatostatin-receptor scintigraphy is not well suited for determin-ing disease spread; the usefulness of DOTATOC (DOTA0-Phe1-Tyr3 octreotid) and fluorodeoxyglucose (FDG) PET/CT scans has not yet been conclusively shown, although recent studies suggest their high sensitivity in detecting organ metastases
56
RE: MCC For primary tumours without signs of organ metastases, complete surgical excision is considered basic therapy. Given the high rate of local recurrences, which generally are due to subclinical satellite metastases, the National Comprehensive Cancer Network recom-mends excision with 1–2 cm margins around the clinically apparent primary tumour if this does not result in functional impairment. SLNB is generally recommended for all patients
Given the very high rate of lymphogenous metastasis of MCC in the head and neck region, an SLNB should not be performed, but rather a functional neck dissection should be considered
57
MCCs are usually highly sensitive to ionising radiation therapy
If an R0 resection is not possible in locoregional tumour manifes-tations, RT may be considered. The total dose for adjuvant treatment is ≥50 Gy with a single dose of 2 Gy five times a week
58
MCC has a high rate of initial response to chemotherapy (c.65%), but the responses are seldom durable and average OS was less than 1 year for metastatic disease.
59
Conversely, even metastatic MCC lesions may regress upon cessation of immunosuppression
60
At present there are no scientifically validated studies on the follow-up care of MCC patients. In general, clinical follow-ups at 3-month intervals are performed given the high risk of local recurrences or regional lymph node metastases in the first 2 years after removal of the primary tumour. However, in high-risk patients 6-weekly clinical follow-ups may be considered. After 2 years, follow-up is recommended at 6-month intervals and may later be prolonged into semiannual visits. At every second visit, besides the clinical examination including lymph node pal-pation, imaging of the regional lymph node stations should be performed. Once a year, an upper abdominal ultrasound and a chest radiograph or CT scans may be considered. The usefulness of FDG-or DOTATOC-PET studies as a part of follow-up has not yet been established. The follow-up period is generally restricted to 5 years given that the majority of recurrences occur during this time.
61
Adaptive immune responses may induce PD-L1 expression on tumour and stroma cells causing exhaustion of tumour-specific T cells, which is particularly relevant in patients with a constricted T-cell receptor repertoire such as elderly patients. Thus, reversal of this immune evasion mechanism through PD-1/PD-L1 blocking antibodies was predicted to be highly efficacious in MCC patients. Indeed, several clinical trials confirmed the efficacy of immune checkpoint blocking antibodies in the treatment of patients with advanced MCC, resulting in the registration of avelumab and pembrolizumab for this indication. A clinical trial using the PD-L1 inhibitor avelumab in patients who had previously progressed after chemotherapy reported response rates of 33% and a 1-year OS of 52% . Avelumab was subsequently tested in treatment-naïve patients, inducing response rates of 62% . The fact that PD-L1 inhibition was less effective when used after chemotherapy sug-gests that the cytotoxic agents may harm immune effector cells and attenuate the response to subsequent immunotherapy. An impres-sive therapeutic effect of inhibiting the PD-1/PDL-1 checkpoint axis in MCC was further confirmed with the PD-1 inhibitor pem-brolizumab. The response rate in treatment-naïve patients was 56%, including 24% complete responders. Importantly, the responses to immunotherapy are not only frequent, but have a rapid onset (days to weeks) and are durable. Due to these characteristics, pembrolizumab and avelumab are now considered the current standard of care for first line treatment of metastatic MCC; up to now these drugs have not been directly compared against each other. While the efficacy of immune checkpoint inhibitors in advanced MCC is impressive, a significant proportion of patients still do not respond at all (primary resistance) or progress after initial clinical benefit (secondary resistance). Whereas possible biomarkers predicting resistance are emerging, they still have not been validated in prospective cohorts. Thus, there still is a significant unmet need for these patients. Multiple clinical trials are investigating RT, other checkpoint inhibitors, oncolytic viruses, Toll-like receptor agonists, cytokine therapy, vaccines, adoptive T-cell therapy, inhibition of the MDM2 protein or epigenetic modifiers as ways to augment immunotherapy responses in MCC.
62
Keratinocyte carcinomas account for more than 97% of all skin cancers
T
63
Increasing incidence of SCC with a ratio of BCC to SCC of 2.5:1
T
64
KCs exceed the prevalence of all other cancers combined, with the average number of lesions per individual varying between1.87and1.64 in Australia and the USA
65
It is estimated that 40–50% of patients with a primary BCC will develop at least one or more BCCs within 5 years
T
66
# Re: BCC In Australia, the most recent data are from 2002 showing age standardised incidence rates to have increased by 35–42% from 1985 to 2002, with the rate in males 1041 per 100 000 person-years and in females 745
T
67
# Re: BCC Indeed, 80% of cases occur in people aged 60 years and over and age is an independent risk factor, with the median age of 71 years at time of diagnosis
68
The 5-year cumulative risk of developing one or more subsequent BCCs is 29.2%. This risk is highest in the first 6 months after first BCC diagnosis. Males are at a 30% higher risk of developing multiple BCCs compared with females.
69
Unlike SCC, for which cumulative lifetime sunexposure shows a strong dose response relationship, for BCC intermittent sunexposure and exposure during childhood maybe more important
T
70
The primary risk factors for BCC development are UV light exposure and genetic predisposition.
T
71
what are the risk factors for development of BCC??
72
Markers which may be useful in differentiating BCCs from trichoepitheliomas include CD-10, Bcl-2, cytokeratin 20 and cytokeratin15v
T
73
what is the mutation for Gorlins?
germline mutations in patched-1 (PTCH1), a segment polarity gene (9q22.3) with tumour suppressor functions. PTCH1 encodes a 12-pass putative trans- membrane protein, which acts like the receptor of the diffusible morphogenprotein sonic hedgehog (SHH) originally identified in the fruitfly Drosophila melanogaster
74
Superficial BCC is usually confined to the papillary dermis
T
75
What is the sonic hedgehog pathway?
PTCH1 acts as a tumour suppressor, repressing the G-protein-coupled receptor smoothened (Smo). Loss-of-function mutations of PTCH1 result in reduced suppression of Smo which activates the Gli family of transcription factors and promotes their importation into the nucleus, resulting in sustained activation of target genes. Gli proteins are bound by Sufu, loss of which produces constitutive activation of Gli. Atypical protein kinase C iota/lambda (aPKC-ι/λ), a novel Gli regulator, and its polarity signalling partners co-localise at the centrosome and form a complex with missing-in-metastasis (MIM) a scaffolding protein that potentiates Hh signalling. Activated aPKC-ι/λ is upregulated in Smo-inhibitor-resistant tumours and targeting aPKC-ι/λ suppresses signalling and growth of resistant BCC cell lines
76
Somatic PTCH1 mutations have a high frequency in familial BCC. Sporadic BCC tumours also demonstrate loss of function of PTCH1 in 80–90% and Smo in10–20% of cases
T
77
White skinned transplant patients have a 10–16-fold higher risk of developing a BCC compared with the non-transplanted population.
T
78
Chroniclymphocytic leukaemia patients are 14 times more likely to suffer recurrences of BCC following Mohs surgery
T
79
Chronic exposure to inorganic arsenic through drinking water has been associated with the development of BCC
T
80
Other risk factors for the development of BCC include UVBphototherapy and ion- ising radiation
T
81
Patients with xeroderma pigmentosum, where DNA repair mechanisms are impaired, can have an up to 2000-fold increased risk of skin cancer
T
82
Prospective study looking at periocular BCC showed surprisingly rapid growth in this cohort with a mean increase in size of 1.46mm in length (area22mm2) every 30 days, with one BCC enlarging by 10 mm in length (area168mm2) in the same time period.
T
83
Epidermoid cysts are associated with BCC naevoid syndrome
T
84
Nodular BCC is the commonest subtype of BCC with a predilection for the head and neck.
T
85
Morphoeic BCCs account for 5% of all BCCs, have ill-defined borders, can be difficult to diagnose clinically and often present late.
86
Re: BCC Advanced cases justify the title ‘ulcus terebrans’ (penetrating ulcer)
T
87
Basosquamous (metatypical) BCC has an increased risk of metastasis in comparison with other BCC subtypes. Up to 38.1% of primary BCCs that metastasise have this subtype despite basosquamous representing <3% of all BCCs
T
88
Superficial BCC is predominantly present on the trunk and limbs. These are thin plaques or patches bounded by a well-circumscribed, slightly raised, thread-like margin which is irregular in outline and may be deficient at part of the circumference. The epidermis covering the central zone is usually scaly and may demonstrate central clearing or atrophy
89
How does imiquimod work?
Imiquimod stimulates Toll-like receptors 7 and 8 expressed on dendritic cells and monocytes, leading to an increased production of cytokines and chemokines. These in turn promote both Th1 innate and adaptive cell-mediated immune responses which are crucial in the recognition and destruction of the tumour cells
90
What is the efficacy of immiquimod for sBCC and nBCC?
Topical 5% imiquimod cream, applied five times per week over 6 weeks, is effective in clearing 69–100% of superficial BCC and 42–76% of nodular BCC on the trunk and limbs There is a lower response rate in nodular BCC and thicker superficial BCC as well as those in high-risk anatomical sites such as the face
91
what are the high risk features of BCC?
92
When compared with PDT, imiquimod may be more effective in treating superficial BCC.
T
93
Imiquimod is recommended for use in superficial BCC in immunocompetent adults, with a maximum tumour diameter of 2.0cm.
T
94
How does topical 5FU work?
Topical 5-fluorouracil (5-FU) disrupts DNA and RNA synthesis by inhibiting the enzyme thymidylate synthetase. This prevents purine and pyrimidine from becoming incorporated into DNA during the S-phase of the cell cycle When compared with imiquimod in the treatment of superficial BCC, 5-FU cream (5%) has similar efficacy and safety
95
PDT was found to be inferior to both imiquimod and 5-FU other than for superficial BCC below the knee in elderly patients
T
96
What is the standard surgcial margin for BCC?
4 mm clinical margin reported 5-year recurrence rates of 0.7–5% for low risk BCC excision with 4mm margin with 3 mm margins, had 18% of excisions incomplete and a 12.2% recurrence rate. If the BCC was recurrent, standard surgical excision showed 32% incomplete excision with a 13.5%recurrence rate If perineural invasion involving nerves >0.1 mm in diameter is seen, consider postoperative radiotherapy and/or multidisciplinary team (MDT) review
97
Destruction of the tissue and a margin of surrounding tissue requires the achievement of lesional temperatures of −50 to -60 is required for BCC
T
98
A double 30 s freeze–thaw cycle for superficial BCC has been reported to have a 95.3% cure rate
T with a recurrence rate of 4–17% with an average 5-year follow-up
99
# Re: C&C Reported 5-year cure rates vary from 91–97% for selected primary BCCs through to 73–81% where higher-risk BCCs are selected
T Hair-bearing areas should be avoided due to potential follicular involvement.
100
Standard surgical excision with wider margins can be considered for highrisk BCC, however the reported surgical margins may need to be up to 15 mm
T
101
In 85–90% of BCCs inactivating mutations are seen in PTCH1, with the remaining 10% having activating mutations in SMO.
T These mutations result in the unchecked activation of the hedgehog pathway, resulting in unregulated proliferation of basal cells leading to BCC development
102
Vismodegib and sonidegib both Smo inhibitors have been developed and used in the treatment of metastatic and locally advanced BCC not considered suitable for surgery or radiotherapy.
T
103
Compared with sonidegib, vismodegib has a higher overall response rate (ORR) of 68.8% versus 56.6%, and complete response rate (CRR) of 30.9% versus 3.0% for locally advanced BCC, and higher ORR of 39.7% versus 14.7% for metastatic BCC with fewer gastrointestinal and muscle side effects
T Prolongation of therapy leads to better responses but may require breaks of weeks to months in therapy to reduce side effects without compromising response. Localised recurrences at the edges of the regressed tumour are seen but are able to be effectively treated with standard surgical excision in most cases.
104
BCC in Gorlins develop between puberty and 35 years of age, with an average age of onset at 25 years
T
105
Palmar pits in a patient with naevoid basal cell carcinoma syndrome. The pits are a useful diagnostic feature that occur in about 65% of adults with NBCCS but are relatively rare in children. They are characterised by small, more or less circular pits, which may have a reddish base and are usually 1–2 mm deep The skin manifestations of the syndrome are varied and include BCCs, skin tags, palmoplantar pits, milia, epi- dermoid cysts and lesions that clinically resemble dermal naevi. Affected individuals may develop up to 500 BCCs in their lifetime
106
Approximately 3% of NBCCS patients develop medulloblastomas, and approximately 3% of patients with medulloblastomas have NBCCS
T
107
Gorlins. Skull X-ray with calcified falx cerebri and a keratocystic odontogenic tumour of the mandible. The keratocystic odontogenic tumours typ- ically occur in the posterior mandible, are usually unilocular, present with radiological lucency and are associated with the crown of an unerupted tooth. Histologically, they show basal cell palisading and hyperplasia. Skeletal abnormalities include spina bifida occulta, bifid or splayed ribs, scoliosis or kyphosis. Less commonly associated anomalies include syndactyly, shortened metacarpals, cleft lip and palate, bicornuate uterus, hypogonadism in males, lymphatic cysts of the mesentery, ocular abnormalities including dystopia canthorum, cataracts and congenital blindness, and a variety of neurological disorders. In addition to BCCs, the syndrome is associated with an increased susceptibility to other neoplasms including rhab- domyosarcoma, ovarian and cardiac fibromas and, in particular, medulloblastoma. Atypical clinical features such as brachydactyly, pulmonary valve stenosis and neurodevelopmental disability should prompt consideration of a contiguous gene deletion syndrome.
108
what is the diagnostic criteria for Gorlin's syndrome?
diagnostic criteria has been refined to include the need for either two major criteria, one major and two minor criteria, or one major with molecular confirmation
109
what investigations are performed for Gorlins?
Suspected cases of NBCCS require a full clinical history and exami- nation, imaging including orthopantogram, spinal, chest and skull X-ray, cardiac and pelvic (female) ultrasound and baseline brain magneticresonance imaging. Molecular genetic testing for heritable pathogenic variants of the PTCH1 and SUFU genes can be undertaken with the probability of detection in up to 60% of cases depending on the clinical diagnostic criteria. Genetic testing does not alter the care of individuals meeting the clinical criteria, but may be helpful in the identification and management of their clinically unaffected relatives. Frequent dermatological screening is recommended with radiological screening for medulloblastoma in those under the age of 8 years and with KOT, usually performed annually.
110
Bazex–Dupré–Christol syndrome (BDCS) is a rare genodermatosis that predisposes affected individuals to multiple BCCs, typically with onset in the second decade of life.
T XLD, only females are affected, Follicular atrophoderma is present at birth or in early childhood, and shows as ‘ice-pick marks’, enlarged follicular ostia on the dorsa of the hands, elbows, feet and face. The follicular changes are not caused by injury or inflammation but there may be facial eczema soon after birth. There may be anhidrosis of the face and head, and hypotrichosis. Milia have been reported as an associated feature. The BCCs appear predominantly on the face typically in the second decade and resemble naevi.Pigmented BCC maybe seen as early as age 5 years
111
Histological variants of AK include atrophic, hypertrophic, lichenoid, acantholytic, pigmented and bowenoid
T
112
Röwert-Huber graded the extent of atypical keratinocytes throughout the epidermis. In grade AK I, atypical keratinocytes are restricted to the lower third of the epidermis. In grade AK II, atypical keratocytes extend to the lower two-thirds of the epider- mis and in grade AK III full thickness atypia of the epidermis is present
113
Clinical pointers favouring the diagnosis of an early invasive SCC vs AK include the presence of tenderness, induration or a raised shoulder that extends beyond the area of disorganised scaling.
T
114
AK can be painful on palpation, in partic- ular if they histologically demonstrate basal proliferation
T
115
Although the rate of progression of an individual AK to invasive SCC has been estimated to be low (less than 1 in 1000/year), an individual with an average of 7.7 AK has a probability of around 10% of one AK transforming to a SCC over a 10-year period
T
116
Dermoscopy can be a useful tool to increase diagnostic precision. Facial non-pigmented AK are characterised by a pink-to-red pseudo network and white-to-yellow surface scales.
T In the case of facial pigmented AK, slate-grey-to-dark brown dots and globules, annular granular structures and a brown-to-grey pseudo-network can be observed
117
Some topical treatments for AK are limited to a maximum application area of 25cm2 by license. These are 5% imiquimod cream, 0.5% fluorouracil with 10% salicylic acid and tirbanibulin ointment.
T
118
What are treatment options for AK field treatment in immunocompromised patients?
PDT (conventional) and 5% 5FU
119
5% 5-fluorouracil cream has shown good efficacy. It has the advantage that it can be applied to large areas up to 500cm2
T efficacy superior to imiquimod and PDT
120
3% diclofenac in 2.5% hyaluronic gel for AK twice daily for 60–90 days. In randomised placebo-controlled double-blind studies, complete clearance rates of 47% compared with 19% for placebo were observed at 30 days follow-up after 90 day
T
121
Imiquimod is a toll-like receptor 7 (TLR7) and TLR8 agonist that upregulates the expression of pro-inflammatory genes. Specifically, it induces translocation of several transcription factors, most importantly nuclear factor (NF)-κB, to the nucleus that activates expression of a multitude of pro-inflammatory genes. Ultimately, there is generation of tumour necrosis factor (TNF) α, interferon (IFN) α, interleukins and chemokines. It also upregulates the pro-apoptotic CD95 receptor thatis known to be down regulated in AK and SCCs.
T 5% imiquimod cream has been compared with placebo in a randomised double-blind study, which showed complete clearance rates of 55% and 2.3%, respectively, at 8-week follow-up after one or two cycles of three times per week over 4 weeks of treatment
122
While 3.75% imiquimod cream can be applied to either whole scalp or whole face, 5% imiquimod cream is limited to a treatment area of 25cm2 by license.
T
123
Tirbanibulin ointment. This is a synthetic inhibitor of tubulin polymerisation leading to microtubular disruption and along with Src kinase signalling inhibition, results in cellular apoptosis.
T (TGA approved)
124
Conventional PDT Applied under occlusion for 3 hours before illumination with red light
T
125
Daylight PDT: Apply to scalp/face; patients should be outdoors within 30 minutes. Patients should stay outside for two continuous hours in full natural daylight. Single treatment, repeat at 3 months if required
T
126
Imiquimod: Apply three times a week to AK on face or scalp for 4 weeks. Assess after a 4-week interval, repeat cycle if required
127
Daylight PDT requires strict adherence to the protocol and adequate illumination conditions (>10∘C, clear conditions, two hours of illumination under sufficient ambient light).
T
128
DSAP is an autosomal dominant disorder with incomplete penetrance early in life
T
129
Risk factors for developing DSAP include genetic factors, UVR exposure and immunosuppression. DSAP commonly occurs on light-exposed skin and has also been reported to occur after narrow-band UVB therapy and after psoralen and UVA (PUVA) therapy.
T
130
Mutations in the mevalonate pathway which involves mevalonate kinase (MVK), mevalonate diphosphate decarboxylase (MVD), farnesyl diphosphate synthase (FDPS) amongst others have been reported in Chinese patients with familial and sporadic DSAP
T The MVK gene maps to chromosome 12q24.11 and DNA sequencing has identified MVK mutations in 33% of familial and 16% of sporadic cases On a background of heterozygous germline mutations in MVK and MVD, it has been demonstrated that a second hit causes somatic homologous recombinations that render the monoallelic mutation biallelic or causes C>T transition mutations in the wild-type allele. As most lesions occur on light-exposed skin, it is likely that this second hit is caused by ultraviolet radiation (UVR).
131
DSAP usually affects light-exposed sites appearing mainly on the distal extremities. The malar regions and the cheeks may be affected but it is not seen on areas habitually covered by clothes, or on the palms or soles. Patients often notice multiple enlarging rough lesions. These tend to be asymptomatic but may be mildly pruritic, particularly after sun exposure and patients often complain of the lesions being unsightly.
132
Porokeratosis variants include porokeratosis of Mibelli, linear porokeratosis, disseminated superficial porokeratosis, porokeratosis palmaris and plantaris diffusa and punctate porokeratosis.
T The rim of DSAP is very much smaller than in Mibelli porokeratosis and never contains a cleft. The onset of Mibelli porokeratosis is often in childhood, and the lesions are usually solitary or few in number and do not necessarily affect exposed parts.
133
The number of lesions tends to increase over time but the risk of malignant change remains very low. In a review of 281 cases with all forms of porokeratosis, the incidence of Bowen disease and SCC was 3.4% in the DSAP group but others have found no increase ininvasive malignancy
134
Individual case with DSAP have been reported to have been successfully treated with topical 2% cholesterol/2% lovastatin cream but not with cholesterol cream alone and 2% cholesterol/2% simvastatin cream
T
135
Bowen's Disease can be found in any part of the skin. It is mostly asymptomatic and expands slowly and centrifugally. The risk of malignant transformation is low (3–5%).
T
136
Variants of bowens disease
verrucous, nodular, eroded, and pigmented variants
137
Historically, arsenic was found in Fowler solution used for psoriasis and Gay solution to treat asthma.
T Long-term arsenic exposure results in impaired immunity characterised by oxidative DNA damage of peripheral polymorphonuclear leu- kocytes and impaired macrophage function in adults with skin lesions
138
Viral agents have been implicated in the aetiology of BD. Interest has centred around HPV with reports of a number of HPV types being present. HPV DNA has been demonstrated in extragenital BD in varying amounts from 4.8% to 60%. Larger studies have failed to confirm these findings, except for HPV16 and HPV18, which are both commoner in anogenital BD and HPV16 has also been implicated in 60% of palmoplantar and periungual lesions
T
139
Bowens disease of the nail unit (subungual, periungual) affects younger women and is associated with high risk HPV types such as HPV16
140
OTRs, who are at an increased risk due to immunosuppression, are at a 153-fold excess risk for developing SCC and dying from it compared with the general population
T
141
SCC carries a high mutational burden and classical tumour suppressor genes (tumour protein 53 (TP53), NOTCH1, NOTCH2, CDKN2A and FAT1) are consistently mutated in SCC.
T
142
TP53 located on chromosome 17p13.1 is a tumour suppressor gene, which helps to repair cells when DNA is damaged by UVR and causes cell apoptosis when the damage cannot be repaired. Mutations of TP53 caused by UVR leading to pyrimidine dimers are frequently seen in AK and approximately 90% of SCCs. The vast majority of TP53 mutations are C>T and CC>TT tandem double transition mutations, considered the ‘mutational signature’ of UV exposure
T
143
Somatic mutations of NOTCH receptors (NOTCH1 and NOTCH2) have been implicated in about 75% of SCCs. Most NOTCH mutations in SCCs result from a G>A transition induced by UVR after homozygous TP53 loss, consistent with evidence of its role in tumour progression
T
144
p16 is also a tumour suppressor protein encoded by the CDKN2A gene in the 9p21 region. It is involved in the arrest of the cell cycle at G1, suppressing the entry into the S phase. p16 mutations can also be caused by UVR. Inactivation of p16 leads to continuous cell cycling and it is thought that inactivated p16 advances AK toSCC
T
145
HRAS mutations are uncommon in human SCC at a frequency of 3–30% but HRAS mutated stem cells are found in human skin, demonstrated by the fact that patients with melanoma treated with BRAF (V-raf murine sarcoma viral oncogene homologue B1) inhibitor, vemurafenib, develop Ras-mutated (mostly HRAS codon 61) KA and SCC within several weeks after starting treatment
146
Histological variants of SCC have been described: classic/nospecial type, acantholytic, spindle cell, desmoplastic, basaloid, verrucous, pseudovascular and follicular.
T
147
Verrucous carcinoma of the foot has been called epithelioma cuniculatum. This is a slow-growing well-differentiated SCC which rarely metastasises. The tumour is characterised by an exophytic verruciform appearance; however, it may exhibit hyperkeratosis, ulceration or a malodorous discharge. The aetiology of verrucous carcinoma is unknown but it can develop in areas of chronic inflammation. HPV has been associated with this tumour and specifically HPV types 11 and 16 have been described in plantar lesions
148
SCC has a low rate of metastasis of about 5%
T
149
What are the high risk features for SCC?
Recommendations for follow-up of high-risk SCC, based on existing evidence, suggest at least a 2-year period with longer follow-up for those on immunosuppression, those with very high-risk disease or multiple tumours
150
RE: SCC After MMS, the pooled estimate of local recurrence was 3% (2.2–3.9%), which was non-significantly lower than the pooled estimate of local recurrence for standard surgical excision (5.4% (2.5–9.1%)) and external radiotherapy (6.4% (3–11%))
T
151
Based on current evidence, a clinical peripheral margin of 4mm is recommended when excising low-risk SCC, 6mm for high-risk SCC and 10mm for very high-risk SCC, where it is surgically achievable and clinically appropriate. Evidence for deep margins remains inconclusive but the tumour should be excised at the anatomical plane deep to the clinically apparent level of tumour invasion.
T
152
When should radiation therapy be considered in the treatment of SCC?
Adjuvant radiotherapy may be an effective therapeutic option in decreasing the risk of tumour progression when a SCC has been excised with close or involved margins, or where completely excised T3 tumours have multiple high-risk features including PNI, depth of >6mm and/or invasion beyond fat
153
In a multicentre randomised controlled trial of 120 OTRs with a history of SCC maintained on ciclosporin or converted to sirolimus, a significantly longer tumour-free survival was demonstrated in the sirolimus group (15 versus 7 months, P= 0.02), with a relative risk of new SCCs in the sirolimus group of 0.56 (95% CI 0.32–0.98)
T
154
Keratoacanthoma (KA) is a rapidly evolving tumour of the skin, composed of keratinising squamous cells originating in pilosebaceous follicles and resolving spontaneously if untreated.
T
155
KA evolves in three clinical phases: proliferative, maturing and resolving
T The process of spontaneous healing usually takes about 3 months.
156
In patients with multiple KA, a family history should be sought to exclude multiple self-healing squamous epithelioma (MSSE). The lack of symptoms such as pruritus and multiple KA only on exposed sites should help exclude generalised eruptive KA (Grzybowski syndrome).
T
157
Xeroderma pigmentosum and Muir–Torre syndrome (MTS) are also associated with KA but other features of MTS include a family history, sebaceous neoplasms and internal malignancy, most commonly carcinoma of the colon.
158
KA will resolve to leave a pitted or unsightly scar. KAs have been rarely reported to metastasise.
159
Dermoscopy of KA has been reported to show hairpin vessels, linear-irregular vessels, targetoid hair follicles, white structureless areas, a central mass of keratin and ulceration, but these features were also found in invasive SCC and therefore not diagnostic of KA
160
The differential diagnosis of multiple self healing squamous epithelioma aka ferguson smith (MSSE) includes generalised eruptive KA (Grzybowski syndrome) but in cases of MSSE there is generally a family history and an earlier age of onset
T
161
In multiple self healing squamous epilioma most tumours regress spontaneously leaving a scar. Patients should be advised about signs of new tumour development and what to look out for: red or flesh coloured nodules usually on light-exposed sites. Advice on high factor broad spectrum sunscreen should be provided. Radiotherapy should be avoided.
T
162
Generalised eruptive KA of Grzybowski is a rare condition with approximately 40 cases being reported in the literature since its first description in 1950. Numerous small, 1–3mm in diameter, flesh-coloured umbilicated papules resembling KAs develop abruptly and may persist for several months.
T Spontaneous regression may occur, which leads to atrophics cars. The mucosal surfaces may be affected as well. Other associated findings include severe pruritus, a Koebner reaction, mask-like facial appearance, ectropion and hoarseness due to nodules on the larynx.
163
What is Muir Torre syndrome?
Autosomal dominant inherited condition which is best regarded as a phenotypic variant of the Lynch II cancer family syndrome. It is characterised by the development of one or more sebaceous neoplasms (sebaceous adenoma, sebaceous epithelioma or sebaceous carcinoma) and/or KA along with one or more visceral malignancies. The majority of cases are familial but sporadic cases have been described. most cases present with cutaneous and/or internal tumours after the fifth decade Most patients are disease free until their sec- ond/third decade when cutaneous tumours may start to arise before internal malignancy (22–32% of cases), concomitantly (6–12%) or after internal malignancy has been diagnosed (56–59%). Sebaceous adenomas are found in 25–68% of patients, sebaceous epitheliomas. In 31–86% and sebaceous carcinomas in 66–100% of cases with MTS. In a single report, all 13 patients with MTS, with mutations in MLH1 and MSH2 genes, had Fordyce granules in the oral mucosa, mainly on the vestibular aspect, which may constitute an additional parameter in diagnosing MTS. KA may occur in about 20% of patients with MTS and may be multiple, on light-protected sites and may occur in younger age groups
164
What is the gene implicated in Muir Torre syndrome?
MTS is caused by germline mutations on one of four DNA mis-match repair (MMR) genes. In about 90% of cases, the mutation occurs in the Mutator S homologue 2 (MSH2) gene which maps to chromosome2p; similar to findings in Lynch syndrome. In fewer than 10% of cases, the mutation is found in the Mutator Lhomolog 1 (MLH1) gene which maps to chromosome 3p. Rarely mutations are found in the Mutator S homolog 6 (MSH6) gene and in post-meiotic segregation increased 2(PMS2) gene MSH6 germline mutations are usually associated with a lower incidence of colon cancer and its later onset but with a higher incidence of extracolonic malignancies, mainly endometrial carcinoma which has an earlier age of onset than colonic carcinoma. BRAF gene mutations can be associated with somatic mutations in the MMR gene and have been found in sebaceous hyperplasia of patients with mutator Y homologue (MYH)-associated polyposis
165
What internal malignancies are associated with Muir Torre?
Most patients develop colorectal carcinoma and nearly 50% have two or more visceral carcinomas. Ten per cent have more than four primary tumours and patients with up to nine tumours have been reported in the literature. Other internal malignancies include carcinoma of the endometrium, stomach, small bowel, genitourinary tract, breast, ovary, pancreas, liver and kidney. There are single reports of an association with non-small cell carcinoma of the lung. Visceral tumours in MTS are usually low-grade malignancies, which tend to permit prolonged survival. The sebaceous carcinomas in this syndrome, like the visceral malignancies, are less aggressive than their counterparts that occur independently. Increased risk of SCC with only mutation status with mainly mutations in MLH1 and MSH2 genes was associated with this risk
166
How do you distinguish between Gardner and MTS?
Gardner syndrome is a subtype of familial adenomatous polyposis with a higher risk of colon carcinoma and multiple colon polyps. However, patients may also develop sebaceous cysts, epidermoid cysts, fibromas, desmoid tumours and osteomas, not features of MTS.
167
How is Muir Torre syndrome managed?
Patients and their family members should be managed using a mul-tidisciplinary approach, mainly between gastroenterologists and dermatologists, with other specialists becoming involved should tumours arise at other body sites. Although evidence for screening is relatively poor, the general recommendations are for patients to have an annual clinical examination, chest radiography and urine cytology. The frequency of performing colonoscopy varies from once every 3 years to every 1–2 years, particularly in higher risk patients. Female patients require an annual cervical smear and carcinoembryonic antigen testing, along with mammography every 1–2 years up to age 50 and then annually thereafter. Endometrial biopsy has also been recommended every 3–5 years. In one report, two patients presenting with cutaneous signs only were found to have colonic malignancy with PET/CT and further stud- ies are required to assess the reliability of this in detecting occult malignancy. Surgical clearance of internal tumours and sebaceous carcinoma should be performed where possible. For patients with solitary or few cutaneous lesions, surgery in the form of excision or curettage and cautery would be appropriate. For patients with multiple benign cutaneous lesions, isotretinoin has been reported to prevent new tumour development.
168
Freckle or ephelis The basal cell layer appears hyperpigmented, without alteration of the epidermal architecture melanocortin1 receptor gene (MCR1) has been characterised as the major freckle gene Dermoscopic image showing hyperpigmented lesions with reticular pattern and moth-eaten edge
169
Name the familial lentiginosis syndromes
Peutz Jegher PTEN (phosphate and tensin homologue) Carney Complex LEOPARD (lentigines, electrocardiogram anomalies, ocular anomalies, pulmonary stenosis, abnormal genitalia, retardation of growth and deafness) (all autosomal dominant)
170
Lentiginosis profusa is a rare condition, with innumerable lentigines present at birth or arising early in life, without systemic abnormalities or mucosal involvement. The disorder has an autosomal dominant inheritance, but its exact genetic background is unknown.
T
171
Agminated or segmental lentiginosis manifests as a circumscribed group of lentigines arranged in a segmental pattern that develop during childhood. They are presumed to represent mosaicism of an unidentified gene and should be differentiated from neurofibromatosis type 1. Melanoma may occur in patients with segmental or generalised lentiginosis.
T
172
Multiple lentigines in a patient with the Carney complex and a PRKAR1A mutation. Only about a third of patients with the complex have this classic pigmentation. Lentigines (lips, conjunctiva, inner or outer canthi, genital mucosa), primary pigmented nodular adrenal cortical disease (PPNAD), cardiac and skin myxomas, schwannomas, acromegaly, breast and testicular tumours
173
Rarely, lentigines arise in the setting of potentially serious hereditary multisystem syndromes related to malignancies. These familial lentiginosis syndromes are characterised by autosomal dominant inheritance and include the Peutz–Jeghers syndrome, the PTEN (phosphate and tensin homologue) hamartomatous syndromes (Ruvalcaba–Myhre–Smith or Bannayan–Zonnana syndromes and Cowden disease), the Carney complex (and the closely related NAME (naevi,atrialmyxoma,myxoidneurofibromaandephelides) and LAMB (lentigines, atrial myxomas, mucocutaneous myxomas and blue naevi) syndromes and the LEOPARD/Noonan syndrome (lentigines, electrocardiogram anomalies, ocular anomalies, pulmonary stenosis, abnormal genitalia, retardation of growth and deafness). Most of these syndromes are caused by mutations in the rat sarcoma–mitogen-actived protein (RAS-MAP) kinase and the mammalian target of rapamycin (mTOR) signalling pathway
174
175
Patients with more than 100 naevi have a sevenfold increase in melanoma risk
T
176
The risk of malignant transformation of an acquired melanocytic naevus is extremely low, ranging on an annual basis from one in 200000 for men and women younger than 40 years, to one in 33000 for men older than 60 years
T
177
Chemotherapy administered for leukaemia in childhood or after renal transplantation has been associated with increased naevus count.
T
178
Individuals with Turner syndrome have increased numbers of melanocytic naevi
179
Local trauma may trigger the development of eruptive naevi in predisposed patients. Hormonal factors in females may also play a role in naevogenesis, as postmenarche status, and the use of oral contraceptives or hormone replacement therapy have been linked with higher naevi count
180
Compound naevus. (a) Hyperpigmented papule surrounded by symmetrical, lighter brown, macular area. (b) Dermoscopic image showing a structureless brown centre with reticulated periphery
181
Re: melanocytic naevi of the breast: these tend to exhibit more atypical characteristics than naevi from other sites, with nesting irregularities, melanocytes with atypia in the papillary dermis and maturation in the deep dermis, and dermal fibroplasia
T
182
melanocytic naevi can be located anywhere in the breast, including the nipple, andareoftenlargerthan6mmwithirregularborders
T
183
Atypical melanocytic naevi of the scalp are more prevalent in younger ages
T
184
Dermoscopic image of acral naevus showing parallel furrow pattern The most common dermoscopic pattern of acral naevi is the parallel furrow pattern, followed by the lattice-like and fibrillar patterns
185
Conjunctival. naevi are similar to those occurring in the skin and present as circumscribed, flat or slightly raised macules or papules, occurring most commonly on the bulbar conjunctiva. They are often amelanotic (30% of cases), particularly in children in whom they often acquire pigmentation after puberty. Attachment to the sclera, extension into the cornea and development of ‘feeder’ vessels upon slit lamp examination represent worrisome changes
186
Combined naevus. (b) Combined naevus with eccentric, structureless, bluish area and peripheral brown, globular pattern
187
A halo naevus is a melanocytic naevus surrounded by a depig- mentedarea resemblinga halo. Dermoscopic image of a halo naevus showing a symmetrical compound naevus (globular pattern) surrounded by a whitish halo. more commonly seen in children, adolescents and young adults AKA: Synonyms and inclusions * Sutton naevus * Leukoderma acquisitum centrifugum * Perinaevoid vitiligo Halo naevi can be associated with autoimmune disorders like vitiligo, Hashimoto thyroiditis, alopecia areata and atopic eczema. The exact pathophysiology of halo naevi is unknown. They are considered an autoimmune response against naevus cells. There is some laboratory evidence of local and circulating immunological T-cell activation in patients with unexcised halo naevi. Stress and puberty are considered to be triggering factors. Familial cases have been reported. Regression of several melanocytic naevi in patients with metastatic melanoma receiving ipilimumab has been observed. Halo naevi have also been observed in relation with imatinib and tocilizumab treatment. Halo naevi are usually compound melanocytic naevi, although junctional or dermal naevi are occasionally noted. At the time of the halo appearing, they demonstrate a heavy, lichenoid, lymphocytic infiltrate within the dermis, with naevus cells arranged in nests or singly among the inflammatory cells. Initially, a rim of depigmentation appears around a pre-existing melanocytic naevus. This white halo is particularly visible during the summer months when the unaffected adjacent skin acquires a tan. During the following months the naevus may gradually shrink or even disappear completely, leaving a white macule. Approximately half of halo naevi undergo total clinical and histological regression. Halo naevi are located primarily in the back. Multiple halo naevi may develop, while other adjacent naevi remain unchanged. Differential diagnosis In older patients presenting a single lesion, the possibility of a melanoma in regression should be excluded. In a case of melanoma, both the central pigmented area and the surrounding halo appear irregular, while the centre of the lesion presents dermoscopic features that are suggestive of melanoma. In suspicious cases, excisional biopsy should be performed. The depigmented area usually persists for a decade or longer. Management: No treatment is required. Patients should be reassured, particularly in case of multiple lesions, and UV protection measures to avoid sunburn of the depigmented skin area is advised. A halo naevus presenting in an older patient should raise concern, especially in the absence of vitiligo and no history of halo naevi in the past. In such cases, a thorough skin and lymph node examination is recommended to exclude melanoma elsewhere.
188
This is a melanocytic naevus that develops an eczematous-like inflammatory reaction. It usually presents in young individuals. Meyerson naevi have been associated with atopic eczema. Treatment with interferon α has been reported prior to the development of Meyerson naevi. Histology reveals a common, usually compound, melanocytic naevus with associated spongiotic dermatitis of the overlying epidermis. Also seen is a dense, perivascular infiltrate in the upper dermis composed mainly of CD4+ lymphocytes and occasionally eosinophils. Severe sunburn has been implicated. Presents as a melanocytic naevus that develops a red-coloured halo with overlying scales. The lesion resembles a naevus with superimposed discoid eczema and it may be slightly pruritic. It usually arises on the trunk and proximal extremities. Multiple lesions can occur. Halo dermatitis has been reported around various benign skin lesions (e.g. common acquired and congenital naevi, Sutton naevi, Spitz naevi, clinically atypical naevi, sebaceous naevus, keloids, insect bites, seborrhoeic keratoses, dermatofibromas) and malignant skin lesions (e.g. melanoma, basal and squamous cell carcinomas). In multiple Meyerson naevi, the differential diagnosis includes pityriasis rosea and roseola of secondary syphilis. The eczematoid changes usually resolve spontaneously after a few months, leaving the involved naevus intact, although some degree of hypopigmentation or even complete resolution of the naevus has been described. Meyerson naevus is a similar lesion to halo naevus and may coexist with this entity in the same patient. Occasionally, a Meyerson naevus can progress to a halo naevus or vice versa. Dermoscopy reveals the benign pattern of the involved melanocytic naevus, often blurred by a yellowish, overlying, superficial serocrust. Normally, the eczematous reaction subsides after 1–2 weeks of treatment with a moderately potent topical steroid. Clinical re-evaluation and dermoscopic examination will confirm that the underlying naevus is benign.
189
Cockade naevus. Dermoscropic image of a cockade naevus showing a darker, central homogeneous pattern, a lighter inner ring and a peripheral brown reticular ring. A cockade naevus is a benign melanocytic lesion with a target-like appearance resembling a rosette. Synonyms and inclusions * Target-like naevus * Kokarden naevus * Naevus en cocarde Usually presents in children and adolescents. It has been proposed that naevus cells in the central and peripheral areas produce melanin more actively, or that there is a lack of melanin synthesis involving the melanocytes of the non-pigmented rim. The central component of the naevus is that of a junctional or compound type, while the periphery of the lesion is composed of junctional nests and may present increased pigment in the dermis. The central component of the naevus is a dark, often papular area, which is surrounded by a non-pigmented circular zone and an outer pigmented ring. Lesions are usually multiple and located on the trunk, or on the scalp in young patients. A target-like appearance has also been reported in association with blue naevi and melanoma. Dermoscopy reveals a naevus with a darker, central globular or homogeneous pattern, surrounded by a structureless inner ring and a more peripheral darker reticular ring A cockade naevus is a benign lesion, thus no treatment is required.
190
A targetoid haemosiderotic naevus derives from mechanical trauma of a melanocytic naevus, which is usually elevated or exophytic. It is common in children and young adults. The upper chest is the most common location. Targetoid haemosiderotic naevus. (a) Naevus acutely presenting with a haemorrhagic halo. (b) Dermoscopic image showing a peripheral, structureless, purple rim around a central pre-existing naevus. Histopathologically, targetoid haemosiderotic naevus consists of naevus cells mingled with extravasated blood vessels and an increased number of irregular, ectatic, vascular channels. The peripheral halo demonstrates extensive haemorrhage with haemosiderin and fibrin deposits combined with slit-shaped vascular channels that dissect in between collagen bundles. A mild, inflammatory,primarily eosinophilic infiltrate is also seen. Targetoid haemosiderotic naevus usually appears as a sudden change of pigmentation in a pre-existing naevus following mechanical irritation, usually from clothing, shaving or scratching. A history of trauma or irritation is not always apparent to the patient. Symptoms indicating trauma such as pain, tenderness or pruritus are common. Clinically, the lesion presents as a brown, red-brown or violaceous papule surrounded by a thin pale area and a peripheral ecchymotic area that tends to expand, become fainter and resolve while the central papule persists. The differential diagnosis includes targetoid haemosiderotic haemangioma, cockade naevus, traumatised angiokeratoma and melanoma. Investigations Dermoscopy reveals haemorrhagic changes with a red to purple colour, surrounding a naevus with a usually globular pattern. Jet-black areas with irregular shape and size as well as comma-shaped vessels are also seen. The periphery of the lesion representing the ecchymotic halo shows an ill-defined, pale area surrounded by a reddish zone with jagged edges. Management Management includes reassurance of the patient and the use of a topical antibiotic or steroid preparation until the inflammatory/ haemorrhagic changes have resolved.
191
A Spitz naevus is a melanocytic lesion characterised by spindled and/or epitheloid naevomelanocytes. Spitz naevi are more commonly seen in younger ages. Approximately 40% of lesions occur in patients under the age of 15 years and 77% before the age of 30. Disseminated,eruptive Spitz naevi have been reported to occur with Addison disease, HIV infection, chemotherapy, puberty and pregnancy. Most lesions area cquired, but up to 7% of Spitz naevi can occur congenitally. The ‘classic’ Spitz naevus typically is asymmetrical and well-defined compound naevus. Naevomelanocytic nests are neatly located between keratinocytes, unlike their disorderly arrangement in melanoma. The naevo melanocytic nests at the dermal–epidermal junction are often separated from the surrounding keratinocytes by a cleft caused by a retraction artefact. The naevus cells may be either spindle shaped, streaming into the dermis in interlacing bundles, or epithelioid, arranged in clusters, with giant and multinucleated naevus cells seen among them. Kamino bodies (i.e. amorphous eosinophilic globules containing periodic acid–Schiff-positive basement membrane constituents) are noted intraepidermally and at the dermal–epidermal junction. Their presence is neither sensitive nor specific for Spitz naevi as they may also be present in early melanoma. In classic Spitz naevi, dermal naevomelanocytic nests and fascicles exhibit a zonation phenomenon with depth, for example uni- formity in size, shape and spacing along horizontal planes. Immunohistochemistry can be used to differentiate Spitz naevi from melanoma. MIB1, which stains the proliferative marker Ki-67, has a lower expression in Spitz naevi compared with melanoma, while HMB-45 is more superficially expressed with diminished staining in the deeper dermal component. S100 and Mart-1 are more weakly stained in Spitz naevi, whereas the S100A6 subtype shows more intense and diffuse expression in Spitz naevi compared with its weak and patchy staining in melanoma. p16 reactivity is stained more intensely in desmoplastic Spitz naevi, while it is largely absent in melanomas. The very rare incidence of NRAS and BRAF mutations in Spitz naevi compared with other melanocytic lesions, and the presence of HRAS mutations in a subgroup of Spitz naevi (c. 20%), suggests a distinct activation of the RAS pathway components in different melanocytic neoplasms. The majority (c. 55%) of Spitz naevi and atypical Spitz tumours have mutually exclusive kinase fusions as primary initiating genomic events. Genomic rearrangements activate oncogenic signalling pathways and involve the kinases ALK, ROS1, NTRK1, NTRK3, BRAF, RET and MET
192
Cellular blue naevus. Dermoscopic image of a cellular blue naevus showing a well-circumscribed, protuberant nodule with homogeneous dark blue pigmentation and randomly distributed whitish zones corresponding histopathologically to fibrosis.
193
Blue naevus. (b) Dermoscopic image of a blue naevus showing a homogeneous blue pattern.
194
10 or more atypical moles conferred a 12-fold risk of melanoma
T the relative risk for melanoma is even greater, reaching 85-fold in melanoma-prone family members with dysplastic naevi
195
BRAFV600E mutation rate is high in both common (∼80%) and dysplastic (∼60%) naevi
T
196
Episodes of painful sunburn before the age of 20 years have been associated with an increased risk for the development of melanocytic naevi (odds ratio (OR) 1.5
T
197
What are the signs of hyperandrogenism?
198
What investigations are performed for. PCOS and. CAH?
199
Absorption of isotretinoin is markedly affected by the presence off at and pharmacokinetic studies show that absorption can be doubled by taking isotretinoin with or after a meal compared with the fasting state
T
200
Trichorexis nodosa is a feature of this rare metabolic defect. Urine and serum amino acids should be analysed in children presenting with TN and hair fragility
T
201
In trichorexis nodosa empirical biotin supplementation (e.g. 2.5–5 mg per day) may be considered.
T
202
Monilethrix on the nape of the neck showing follicular keratoses and short, broken hairs. The hair shaft is beaded and breaks easily, particularly at sites of friction. Broken hair may be accompanied by follicular keratosis, most commonly on the nape and occiput
203
Pili torti Affected hairs are brittle and may break off, particularly in areas subject to trauma, such as the occiput. Affected hairs have a spangled appearance in reflected light. Non-scalp areas (e.g. eyebrows/eyelashes) may also be affected. Rotations of the hair shaft run in groups of three to five twists before the shaft normalises. Assessment of hearing loss, serum copper/ceruloplasmin levels and/or nutritional deficiencies should be done depending on the clinical presentation
204
Trichorrhexis invaginata The hair in Netherton syndrome is short, dry, lustreless and fragile. The eyebrows and eyelashes are sparse or absent. Unfortunately, the diagnostic hair changes of trichorrhexis invaginata can vary over time and location. Therefore, it is important that samples of at least 100 hairs are carefully examined by light microscopy on several occasions before a definite negative is asserted. Alternatively, finding a single trichorrhexis invaginata node in a single hair is a conclusive positive. Consider sampling eyebrows hairs as this is shown to increase the likelihood of successful diagnosis. Unfortunately, the diagnostic hair changes of trichorrhexis invaginata can vary over time and location. Therefore, it is important that samples of at least 100 hairs are carefully examined by light microscopy on several occasions before a definite negative is asserted. Alternatively, finding a single trichorrhexis invaginata node in a single hair is a conclusive positive
205
Pili annulati is often diagnosed coincidentally due torecognition of the unusual shiny, spangled appearance of the hair. The light bands identified by eye represent the air-filled cavities that are more easily seen in lighter hair colours.
206
Uncombable hair Pili triangulati et canaliculi Hair is normal in quantity and sometimes also in length, but the wild, disorderly appearance totally resists all efforts to control it with a brush or comb. The hair is often a silvery blond colour. The eye brows and eyelashes are normal. The hairs are triangular or kidney-shaped in cross-section and longitudinal grooving is identified. Recently, techniques to identify the hairs in cross-section using epoxy resin or frozen sectioning have been described. Samples should show >50% abnormal hairs to make the diagnosis.
207
Typically, loose anagen syndrome is seen in fair-haired children, aged 2–9 years and mostly girls. The hair is slightly unruly, of uneven length and patchy in quality, with a history of not growing properly and never needing cutting. Hair is usually easily and painlessly plucked from the scalp. Diagnosis is suggested when 3–10 anagen hairs are easily removed using the hair pull test, although caution is required as the numbers of hairs removed can vary over time, so a single negative hair pull does not exclude the diagnosis. Diagnosis can be confirmed by trichogram and requires at least 70% of hairs to be loose anagen hairs. Microscopy of loose anagen hairs shows ruffling of the cuticle adjacent to the anagen bulb, giving the appearance of a ‘floppysock’, along with the absence of an attached root sheath (helping to differentiate these hairs from normal plucked anagen hairs). 61% of normal children under 10 years have some degree of loose anagen hairs on hair pull, although the numbers of hairs removed were small (one or two loose anagen hairs per pull) compared with significantly higher numbers seen in loose anagen syndrome. This may reflect immature anchoring and higher anagen levels in this younger age group.
208